Zacks says the pair made up about 65% of Lilly's revenue ahead of Q3 results on Oct. 29, while the new Foundayo pill booked $98 million in its first quarter.
Recap by typeshit. Full story at Yahoo Finance.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
ABC News' chief medical correspondent walks through the latest Novo Nordisk GLP-1 medication and what sets it apart from drugs already on the market.
18:51
A doctor walks through four of the most talked about weight loss drugs in one overview, covering the big names people ask about most.
Investseekers shares notes on the upcoming French rollout of the Wegovy pill and where Novo Nordisk might launch it next in Europe.
Health records from 131 million adults linked GLP-1s to fewer dialysis or transplant cases. The researchers stress the study is observational and can't prove cause.
A JAMA Network Open study of 2,316 patients in four cities found BMI couldn't separate clinical from preclinical obesity. Authors see a role for drugs first in some cases.
Loading…